Related Experiment Video

Updated: Sep 15, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment

D Autran1, N Attia, M Dedecjus

  • 1Laboratoire de Métabolisme des Lipides, Université Lyon 1, H pital de l'Antiquaille, France.

Atherosclerosis
|February 13, 2001
PubMed

Insights

Bezafibrate improved reverse cholesterol transport (RCT) in type 2 diabetic patients by restoring fasting cholesterol efflux and reducing HDL triglycerides. This suggests bezafibrate may mitigate cardiovascular risk associated with impaired RCT in diabetes.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Metabolic Research

Background:

  • Reverse cholesterol transport (RCT) is a key anti-atherogenic process.
  • Impaired RCT and postprandial lipemia contribute to cardiovascular risk in type 2 diabetes.
  • Bezafibrate's effect on postprandial RCT in diabetic patients is not well understood.

Purpose of the Study:

  • To investigate if bezafibrate improves postprandial RCT in type 2 diabetic patients.
  • To explore the relationship between postprandial lipolysis, HDL composition, and RCT.
  • To assess bezafibrate's impact on fasting and postprandial cholesterol efflux and HDL metabolism.

Main Methods:

  • Twelve male type 2 diabetic patients and seven controls were studied.
  • Lipoproteins were analyzed 8 hours after a high-fat meal.
  • Serum-mediated cholesterol efflux was measured using 3H-cholesterol labeled Fu5AH cells.
  • Patients received 400 mg bezafibrate for 4 weeks.

Main Results:

  • Diabetic patients showed lower fasting cholesterol efflux and a postprandial decrease instead of an increase.
  • HDL in patients failed to acquire phospholipids and gained triglycerides postprandially.
  • Bezafibrate treatment improved fasting efflux and overall postprandial efflux (AUC).
  • HDL triglyceride levels negatively correlated with postprandial efflux.

Conclusions:

  • Impaired RCT in type 2 diabetes may stem from reduced postprandial phospholipid transfer and increased HDL triglyceride accumulation.
  • Bezafibrate treatment shows potential in improving RCT in diabetic patients, possibly by reducing HDL triglycerides and improving postprandial hyperlipemia.

Related Concept Videos

Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.